A Krebs-cycle metabolite eased lupus and restored mitochondrial gene activity in kidney tissue — in mice

Edited by Samael A. Tejada, Founder & Editor-in-Chief

AKG is not a foreign drug; it is one of the cycle's own intermediates, and this study reads like topping up a depleted engine part: autoantibodies down, kidneys protected, respiratory-chain genes back on, ATP up. It is also one dose, one induced mouse model, and a compound already sold in longevity supplements whose marketing will travel much further than this paper's careful caveats.

How was the lupus experiment designed?

Eight-week-old female BALB/c mice were injected with pristane, an established method of inducing lupus-like autoimmunity, and the model was confirmed over five months before treatment began. Mice then received AKG by gavage at 100 mg/kg/day — the dose used in this published study, chosen from prior reports — or water, for three months, in four groups of 14 (healthy control, healthy plus AKG, lupus, lupus plus AKG). The team assessed kidney structure and function histologically, serum autoantibodies and biochemistry, oxidative-stress markers, mitochondrial biogenesis-related factors and respiratory-chain gene expression, spleen immune-cell proportions and interferon-stimulated gene expression. The disease was severe: multiple untreated lupus mice developed ascites and died, leaving 6 of 14 survivors, while 12 of 14 AKG-treated lupus mice survived the full procedure.

What did AKG change — and what is the mitochondrial part of the story?

On the disease readouts, AKG reduced antinuclear antibodies, lessened renal injury and glomerular damage, lowered IgG deposition measures and improved serum biochemical indices. On oxidative stress, it raised the capacity of endogenous antioxidant enzymes and lowered malondialdehyde, a marker of lipid oxidative damage. The mitochondrial findings were direct: AKG upregulated transcriptional levels of mitochondrial respiratory-chain complex genes and increased ATP production in kidney tissue, and the authors summarize its protection as including improved mitochondrial biogenesis-related factors. Immunologically, AKG regulated spleen immune-cell proportions and decreased interferon-stimulated gene expression and inflammatory cytokine release — notable because the type I interferon signature is a core driver of human lupus.

What stands between this mouse result and a lupus patient?

The authors state the main gaps themselves: a single dose was tested, so neither the dose-response curve nor an optimal dose is known, and safety and dose-finding studies are required before any clinical experiment. Pristane-induced disease in inbred female mice models parts of lupus, not the genetically and clinically heterogeneous human disease, and gavage dosing of a pure compound is not equivalent to any supplement a consumer can buy — AKG products vary, and none is approved or dosed for lupus. The fair reading is a coherent, multi-pathway mouse result for a mitochondrial metabolite in an autoimmune disease with a real mitochondrial-dysfunction component — promising enough to justify the dose-response work the authors call for, and nothing beyond that yet.

Where the evidence stands

• Established: Alpha-ketoglutarate is a central tricarboxylic-acid-cycle intermediate linking mitochondrial energy metabolism to immune regulation; mitochondrial dysfunction and oxidative stress contribute to lupus pathogenesis, and a type I interferon signature drives much human disease.
• Preliminary: In pristane-induced lupus mice (Nutrients, Oct 30, 2026), three months of AKG at the published study dose of 100 mg/kg/day reduced antinuclear antibodies and kidney injury, improved survival (12/14 vs 6/14), lowered oxidative stress, upregulated mitochondrial respiratory-chain genes and increased kidney ATP production.
• Absent: Human evidence of any kind, dose-response and safety characterization (a single dose was used, per the authors), and any approved AKG product or dose for lupus.